Friday , April 20 2018
Home / Health / Novartis says Votubia receives EU approval for new indication

Novartis says Votubia receives EU approval for new indication


ZURICH (Reuters) – Novartis has broadened the indications for its Votubia drug, the corporate stated on Tuesday, when the European Union authorised its use to deal with refractory partial-onset seizures in sufferers with tuberous sclerosis complicated.

Votubia is the primary adjunctive remedy authorised within the EU particularly for partial-onset seizures in youngsters and adults with tuberous sclerosis complicated, the Basel-based prescription drugs firm stated in a press release.

The choice marks the third TSC-related indication for Votubia within the EU, the place it’s also permitted to deal with subependymal big cell astrocytoma and renal angiomyolipomas.

Tuberous sclerosis complicated is a uncommon genetic dysfunction affecting as much as a million individuals worldwide. Approximately 85 % of people with TSC are affected by epilepsy, and uncontrolled seizures related to TSC could be debilitating for sufferers.

(Reporting by John Revill)


Source link

Check Also

Female pattern baldness: Treatment and genetics

While most women lose between 50 and 100 strands of hair per day, this hair …

Leave a Reply

Your email address will not be published. Required fields are marked *

*